Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Common Immunosuppressive Monotherapy for Graves’ Ophthalmopathy: A Meta-Analysis
source: PloS One
authors: Mou P, Jiang LH, Zhang Y, Li YZ, Lou H, Zeng CC, Wang QH, Cheng JW, Wei RLsummary/abstract:
Several immunosuppressive therapeutic regimens are widely used to treat Graves’ ophthalmopathy (GO), including oral glucocorticoids (OGC), intravenous glucocorticoids (IVGC), retrobulbar injections of glucocorticoids (ROGC) and orbital radiotherapy (OR). The priority among these is unknown. This meta-analysis investigated the efficacy and tolerability of the above regimens.
The PubMed, EMBASE, and Cochrane Library databases and the Chinese Biomedicine Database were searched up to November 18, 2014. Randomized controlled trials (RCTs) comparing monotherapies (OGC, IVGC, ROGC and OR) in patients with moderate-to-severe active GO were selected. The main efficacy measures were the response rate, the standard mean difference (SMD) in the reduction in the clinical activity score (CAS) and the mean difference (MD) in proptosis from baseline to the end of treatment. The main tolerability measure was the risk ratio (RR) for adverse events. The pooled estimates and 95% confidence intervals (95% CIs) were calculated using the RevMan software, version 5.1.
Seven published RCTs involving 328 participants were included in the present meta-analysis, including IVGC versus OGC (3 trials), ROGC versus OGC (3 trials) and OR versus OGC (1 trial). IVGC was more effective than OGC in response rate (RR = 1.48, 95% CI = 1.18-1.87) and had an obvious CAS reduction (SMD = 0.69, 95% CI = 0.13-1.25). IVGC caused fewer adverse events than OGC. ROGC and OGC had no statistically significant difference in response rate (RR = 1.16, 95% CI = 0.94-1.42). OR also did not differ significantly compared with OGC (RR = 0.93, 95% CI = 0.54-1.60). ROGC and OR had fewer adverse events, such as weight gain, compared with OGC.
For patients with GO in the moderate-to-severe active phase, current evidence gave priority to IVGC, which had a statistically significant advantage over OGC and caused fewer adverse events. ROGC and OR did not provide greater efficacy than OGC, although better tolerability and fewer adverse events were shown.
read more full text
Randomized Controlled Trial of Rituximab in Patients With Graves’ OrbitopathyContext: Graves' orbitopathy (GO) is a ...
TED and Smoking: Information for PatientsHyperthyroidism is a condition where the...
Warning Signs of Graves’ Disease and Thyroid Eye Diseasehttps://mms.businesswire.com/media/20190...
Early Diagnosis of Thyroid Eye Disease (TED)Early Symptoms TED can first present wi...
The UC San Diego Thyroid Eye ClinicThe University of California (UC) San Di...
Smoking was Associated With Poor Response to Intravenous Steroids Therapy in Graves’ OphthalmopathyBackground: Previous studies have shown...
Living Well With Thyroid Eye Disease – Webinarhttps://www.youtube.com/watch?v=45_mIC7b...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.